GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+7.15%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$637M
AUM Growth
+$637M
(+0.62%)
Cap. Flow
-$27.7M
Cap. Flow
% of AUM
-4.34%
Top 10 Holdings %
Top 10 Hldgs %
61.72%
Holding
42
New
9
Increased
10
Reduced
9
Closed
11
Top Buys
| 1 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$28.5M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$18M |
| 3 |
United Therapeutics
UTHR
|
$16.7M |
| 4 |
Exelixis
EXEL
|
$13.1M |
| 5 |
VYNE Therapeutics
VYNE
|
$12.8M |
Top Sells
| 1 |
PTC Therapeutics
PTCT
|
$40M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$34.8M |
| 3 |
NovoCure
NVCR
|
$22.3M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$16.7M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$13.7M |
Sector Composition
| 1 | Healthcare | 96.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioCryst Pharmaceuticals
BCRX
$1.74B
| $60.9M | 9.49% | 7,978,275 +500,000 | +7% | +$3.81M |
|
|
XLRN
2
DELISTED
Acceleron Pharma Inc.
XLRN
| $52.5M | 8.19% | 917,767 +159,767 | +21% | +$9.14M |
|
3
Larimar Therapeutics
LRMR
$310M
| $39.6M | 6.18% | 3,391,385 -108,615 | -3% | -$1.27M |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $39.3M | 6.13% | 3,496,340 +10,595 | +0.3% | +$119K |
|
|
5
United Therapeutics
UTHR
$13.8B
| $38.4M | 5.98% | 300,000 +130,361 | +77% | +$16.7M |
|
6
Kura Oncology
KURA
$686M
| $37.1M | 5.78% | 2,119,106 -508,004 | -19% | -$8.89M |
|
|
7
Exelixis
EXEL
$10.1B
| $36.8M | 5.73% | 2,075,000 +740,207 | +55% | +$13.1M |
|
|
8
PTC Therapeutics
PTCT
$3.92B
| $33.7M | 5.26% | 717,458 -851,042 | -54% | -$40M |
|
|
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $28.5M | 4.45% | +1,606,100 | New | +$28.5M |
|
10
Voyager Therapeutics
VYGR
$186M
| $26.5M | 4.13% | 1,400,000 +669,990 | +92% | +$12.7M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $26.3M | 4.09% | 300,000 +39,900 | +15% | +$3.49M |
|
12
Savara
SVRA
$567M
| $25M | 3.9% | 2,243,084 +1,068,543 | +91% | +$11.9M |
|
|
13
Acadia Pharmaceuticals
ACAD
$4.38B
| $24.8M | 3.87% | 1,196,098 -803,902 | -40% | -$16.7M |
|
|
FOMX
14
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $23.1M | 3.6% | 4,030,268 -751,440 | -16% | -$4.31M |
|
|
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $22.9M | 3.57% | 1,647,753 +387,753 | +31% | +$5.4M |
|
16
Cytokinetics
CYTK
$4.23B
| $21.5M | 3.35% | 2,179,688 +735,207 | +51% | +$7.24M |
|
|
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $21.4M | 3.34% | 393,147 -106,853 | -21% | -$5.83M |
|
|
18
Enanta Pharmaceuticals
ENTA
$180M
| $18M | 2.8% | +210,400 | New | +$18M |
|
|
19
VYNE Therapeutics
VYNE
$8.16M
| $12.8M | 2% | +1,304,407 | New | +$12.8M |
|
20
TG Therapeutics
TGTX
$4.65B
| $10.9M | 1.7% | +1,950,000 | New | +$10.9M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $10.1M | 1.58% | 982,449 -491,160 | -33% | -$5.05M |
|
22
argenx
ARGX
$43.6B
| $9.79M | 1.53% | +129,060 | New | +$9.79M |
|
23
Madrigal Pharmaceuticals
MDGL
$9.76B
| $8.65M | 1.35% | +40,400 | New | +$8.65M |
|
24
Zymeworks
ZYME
$1.12B
| $3.8M | 0.59% | +241,970 | New | +$3.8M |
|
|
VIRX
25
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $2M | 0.31% | +1,000,000 | New | +$2M |
|